Shire PLC

Canada's Valeant to acquire Salix in $10.1 billion deal

Canada's Valeant Pharmaceuticals International Inc. agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd. (SLXP.O) in an all-cash deal valued at about $10.1 billion, the two companies said on Sunday.

Read Full Article

Shire to buy NPS for $5.2 billion to boost rare disease drugs

Shire Plc has agreed to buy NPS Pharmaceuticals Inc for $5.2 billion in its biggest acquisition yet, as the Dublin-based drugmaker strengthens its position in the lucrative field of medicines for rare diseases.

Read Full Article

Elliott Associates may sue AbbVie over scuttled deal

Hedge fund Elliott Associates may take legal action against pharmaceuticals company AbbVie Inc for scuttling a merger deal with Shire Plc.

Read Full Article

AbbVie says to reconsider recommendation for Shire acquisition

AbbVie Inc (ABBV.N) said it intends to reconsider its recommendation to its shareholders to vote in favor of the 32 billion pound ($54.7 billion) merger with Shire Plc (SHP.L) due to the changing U.S. tax regulations.

Read Full Article

Shire Plc purchases ViroPharma

The USD4.2 billion purchase by Shire Plc of ViroPharma Inc is the highest purchase on EBITDA rates for a biotechnology firm in history, as the price is 58 times EBITDA.

Read Full Article

ViroPharma to hire Goldman Sachs for possible sale

ViroPharma had attracted interested suitors including Sanofi and Shire Plc. as it started working with Goldman Sachs Group for a possible sale.

Read Full Article

Shire, Teva Pharmaceutical Settle Patent on Intuniv

Shire Plc (SHP) pulled off a settlement agreement with Teva Pharmaceutical Industries Ltd. (TEVA), enabling the later to manufacture cheap generic copies of Intuniv.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics